Angileri Salvatore Alessio, Pellegrino Giuseppe, Lanza Carolina, Pozzi Jacopo, Costa Marco, Pavan Matilde, Biondetti Pierpaolo, Carriero Serena, Ascenti Velio, Amato Gaetano Valerio Davide, Torcia Pierluca, Ierardi Anna Maria, Carrafiello Gianpaolo
Department of Diagnostic and Interventional Radiology, Foundation IRCCS Cà Granda-Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.
Department of Oncology and Hemayo-Oncology, Università degli Studi di Milano, 20122 Milan, Italy.
Diagnostics (Basel). 2025 Apr 22;15(9):1060. doi: 10.3390/diagnostics15091060.
: the aim of this study was to evaluate the safety and efficacy of percutaneous transhepatic lithotripsy using the SpyGlassDSTM cholangioscopy system for the treatment of difficult stones. : Retrospectively, all patients treated with percutaneous transhepatic lithotripsy using SpyGlassDSTM cholangioscopy system were analyzed. As primary outcome measures, the following data were assessed: the presence of a previous history of the hepatobiliary disease, location of stones, reasons for the choice of the procedure, previous balloon bilioplasty, type of pre-procedural imaging, procedural time, technical success, clinical success, and post-procedural complications (according to CIRSE classification). Clinical success was considered "primary" when achieved with a single treatment, and "secondary" if more than one treatment was required in the duration of follow-up. : 10 patients (6 males and 4 females, mean age = 64 years, SD = 22), all with cholangitis due to gallstones, underwent 11 PTL procedures using SpyGlassDSTM. Technical and clinical successes were achieved in all patients (100%). Primary success was observed in 4/10 (40%) patients, while the remaining 6/10 (60%) patients undergoing re-treatment, and all showed secondary success (100%). No periprocedural complications were observed. In 10/11 procedures (90%), no relevant adverse events were recorded within the first thirty days of follow-up. In 1/11 case (9%), mild complications (grade I according to CIRSE classification) were registered in the following days after the procedure (<30 days). : in conclusion, the treatment of percutaneous transhepatic lithotripsy using SpyGlassDSTM cholangioscopy of difficult stones has been demonstrated as efficient and safe treatment.
本研究的目的是评估使用SpyGlassDSTM胆管镜系统经皮经肝胆道碎石术治疗难取性结石的安全性和有效性。回顾性分析所有使用SpyGlassDSTM胆管镜系统经皮经肝胆道碎石术治疗的患者。作为主要观察指标，评估以下数据：肝胆疾病既往史、结石位置、选择该手术的原因、既往球囊胆管成形术、术前影像学类型、手术时间、技术成功率、临床成功率以及术后并发症（根据CIRSE分类）。单次治疗取得的临床成功被视为“一次成功”，随访期间需要多次治疗则为“二次成功”。10例患者（6例男性，4例女性，平均年龄 = 64岁，标准差 = 22），均因胆结石并发胆管炎，接受了11次使用SpyGlassDSTM的经皮经肝胆道碎石术。所有患者均取得技术和临床成功（100%）。4/10（40%）例患者观察到一次成功，其余6/10（60%）例患者接受再次治疗，均显示二次成功（100%）。未观察到围手术期并发症。11例手术中有10例（90%）在随访的前30天内未记录到相关不良事件。1/11例（9%）在术后数天（<30天）记录到轻度并发症（根据CIRSE分类为I级）。总之，使用SpyGlassDSTM胆管镜经皮经肝胆道碎石术治疗难取性结石已被证明是一种安全有效的治疗方法。
